✦ LIBER ✦

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

✍ Scribed by Coric, Vladimir; van Dyck, Christopher H.; Salloway, Stephen; Andreasen, Niels; Brody, Mark; Richter, Ralph W.; Soininen, Hilkka; Thein, Stephen; Shiovitz, Thomas; Pilcher, Gary; Colby, Susan; Rollin, Linda; Dockens, Randy; Pachai, Chahin; Portelius, Erik; Andreasson, Ulf; Blennow, Kaj; Soares, Holly; Albright, Charles; Feldman, Howard H.; Berman, Robert M.

Book ID: 121002128
Publisher: American Medical Association
Year: 2012
Tongue: English
Weight: 239 KB
Volume: 69
Category: Article
ISSN: 0003-9942
DOI: 10.1001/archneurol.2012.2194

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and tolerability of BMS-708163 in

Safety and tolerability of BMS-708163 in a phase II study in mild-to-moderate Alzheimer's disease

✍ Salloway, Stephen; Coric, Vlad; Brody, Mark; Andreasen, Niels; van Dyck, Christo 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 82 KB

A phase II study of the gamma-secretase

A phase II study of the gamma-secretase inhibitor avagacestat (BMS-708163) in predementia Alzheimer's disease

✍ Coric, Vlad; Salloway, Stephen; van Dyck, Christopher; Kerselaers, Wendy; Kaplit 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Cerebral microbleeds in a phase 2 clinic

Cerebral microbleeds in a phase 2 clinical trial of mild-to-moderate Alzheimer's disease with the gamma secretase inhibitor BMS-708163

✍ Feldman, Howard; Coric, Vlad; Sperling, Reisa; Greenberg, Steven; Bronen, Richar 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 53 KB

O2-05-08: A phase III study of the effic

O2-05-08: A phase III study of the efficacy, safety and disease modification effect of tramiprosate in mild-to-moderate Alzheimer’s disease

✍ Paul Aisen; Serge Gauthier; Richard Briand; Daniel Saumier; Graziella Soulban; D 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Efficacy and safety of tarenflurbil in m

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

✍ Gordon K Wilcock; Sandra E Black; Suzanne B Hendrix; Kenton H Zavitz; Edward A S 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 199 KB

Safety, tolerability, and preliminary ef

Safety, tolerability, and preliminary efficacy of SAM-531, a 5HT-6 antagonist, in subjects with mild-to-moderate Alzheimer's disease: Results from a phase 2a study

✍ Claudine Brisard; Beth Safirstein; Kevin Booth; Lisa Hua; Yves Brault; Sangeeta 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB